Cargando…

Antibody response to BNT162b2 SARS-CoV-2 mRNA vaccine in adult patients with systemic sclerosis

OBJECTIVES: Systemic sclerosis (SSc) patients are at risk for a severe disease course during SARS-CoV-2 infection either due to comorbidities or immunosuppression. The availability of SARS-CoV-2 vaccines is crucial for the prevention of this hard-to-treat illness. The aim of this study is to assess...

Descripción completa

Detalles Bibliográficos
Autores principales: Pellicano, Chiara, Campagna, Roberta, Oliva, Alessandra, Leodori, Giorgia, Miglionico, Marzia, Colalillo, Amalia, Mezzaroma, Ivano, Mastroianni, Claudio Maria, Turriziani, Ombretta, Rosato, Edoardo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9132599/
https://www.ncbi.nlm.nih.gov/pubmed/35614287
http://dx.doi.org/10.1007/s10067-022-06219-7
_version_ 1784713413908234240
author Pellicano, Chiara
Campagna, Roberta
Oliva, Alessandra
Leodori, Giorgia
Miglionico, Marzia
Colalillo, Amalia
Mezzaroma, Ivano
Mastroianni, Claudio Maria
Turriziani, Ombretta
Rosato, Edoardo
author_facet Pellicano, Chiara
Campagna, Roberta
Oliva, Alessandra
Leodori, Giorgia
Miglionico, Marzia
Colalillo, Amalia
Mezzaroma, Ivano
Mastroianni, Claudio Maria
Turriziani, Ombretta
Rosato, Edoardo
author_sort Pellicano, Chiara
collection PubMed
description OBJECTIVES: Systemic sclerosis (SSc) patients are at risk for a severe disease course during SARS-CoV-2 infection either due to comorbidities or immunosuppression. The availability of SARS-CoV-2 vaccines is crucial for the prevention of this hard-to-treat illness. The aim of this study is to assess the humoral response after mRNA vaccination against SARS-CoV-2 in SSc patients. METHOD: Seropositivity rate and serum IgG levels were evaluated 1 month (t1) and 3 months (t3) after the second dose of vaccine in a cohort of SSc patients and healthy controls (HC). Differences were made with Student’s or Mann–Whitney’s t-test and with the chi-square or Fisher exact test. Logistic regression model including immunosuppressive treatments (corticosteroids, CCS; mycophenolate mofetil, MMF; methotrexate, MTX; rituximab, RTX) was built to assess the predictivity for seropositivity. RESULTS: The seropositivity rate was similar in 78 SSc patients compared to 35 HC at t1 but lower at t3. SSc patients had lower serum IgG levels than HC at t1 but not at t3. SSc patients treated with immunosuppressive therapy showed both a lower seropositive rate (t1, 90.3% vs 100%; t3, 87.1% vs 97.9%; p < 0.05) and serum IgG levels than untreated patients both at t1 [851 BAU/ml (IQR 294–1950) vs 1930 BAU/ml (IQR 1420–3020); p < 0.001] and t3 [266 BAU/ml (IQR 91.7–597) vs 706 BAU/ml (IQR 455–1330); p < 0.001]. In logistic regression analysis, only MTX was significant [OR 39.912 (95% CI 1.772–898.728); p < 0.05]. CONCLUSIONS: SSc patients treated with MTX had a lower serological response to mRNA vaccine, and even low doses of CCS can adversely affect antibody titer and vaccination response.
format Online
Article
Text
id pubmed-9132599
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Springer International Publishing
record_format MEDLINE/PubMed
spelling pubmed-91325992022-05-26 Antibody response to BNT162b2 SARS-CoV-2 mRNA vaccine in adult patients with systemic sclerosis Pellicano, Chiara Campagna, Roberta Oliva, Alessandra Leodori, Giorgia Miglionico, Marzia Colalillo, Amalia Mezzaroma, Ivano Mastroianni, Claudio Maria Turriziani, Ombretta Rosato, Edoardo Clin Rheumatol Original Article OBJECTIVES: Systemic sclerosis (SSc) patients are at risk for a severe disease course during SARS-CoV-2 infection either due to comorbidities or immunosuppression. The availability of SARS-CoV-2 vaccines is crucial for the prevention of this hard-to-treat illness. The aim of this study is to assess the humoral response after mRNA vaccination against SARS-CoV-2 in SSc patients. METHOD: Seropositivity rate and serum IgG levels were evaluated 1 month (t1) and 3 months (t3) after the second dose of vaccine in a cohort of SSc patients and healthy controls (HC). Differences were made with Student’s or Mann–Whitney’s t-test and with the chi-square or Fisher exact test. Logistic regression model including immunosuppressive treatments (corticosteroids, CCS; mycophenolate mofetil, MMF; methotrexate, MTX; rituximab, RTX) was built to assess the predictivity for seropositivity. RESULTS: The seropositivity rate was similar in 78 SSc patients compared to 35 HC at t1 but lower at t3. SSc patients had lower serum IgG levels than HC at t1 but not at t3. SSc patients treated with immunosuppressive therapy showed both a lower seropositive rate (t1, 90.3% vs 100%; t3, 87.1% vs 97.9%; p < 0.05) and serum IgG levels than untreated patients both at t1 [851 BAU/ml (IQR 294–1950) vs 1930 BAU/ml (IQR 1420–3020); p < 0.001] and t3 [266 BAU/ml (IQR 91.7–597) vs 706 BAU/ml (IQR 455–1330); p < 0.001]. In logistic regression analysis, only MTX was significant [OR 39.912 (95% CI 1.772–898.728); p < 0.05]. CONCLUSIONS: SSc patients treated with MTX had a lower serological response to mRNA vaccine, and even low doses of CCS can adversely affect antibody titer and vaccination response. Springer International Publishing 2022-05-26 2022 /pmc/articles/PMC9132599/ /pubmed/35614287 http://dx.doi.org/10.1007/s10067-022-06219-7 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Original Article
Pellicano, Chiara
Campagna, Roberta
Oliva, Alessandra
Leodori, Giorgia
Miglionico, Marzia
Colalillo, Amalia
Mezzaroma, Ivano
Mastroianni, Claudio Maria
Turriziani, Ombretta
Rosato, Edoardo
Antibody response to BNT162b2 SARS-CoV-2 mRNA vaccine in adult patients with systemic sclerosis
title Antibody response to BNT162b2 SARS-CoV-2 mRNA vaccine in adult patients with systemic sclerosis
title_full Antibody response to BNT162b2 SARS-CoV-2 mRNA vaccine in adult patients with systemic sclerosis
title_fullStr Antibody response to BNT162b2 SARS-CoV-2 mRNA vaccine in adult patients with systemic sclerosis
title_full_unstemmed Antibody response to BNT162b2 SARS-CoV-2 mRNA vaccine in adult patients with systemic sclerosis
title_short Antibody response to BNT162b2 SARS-CoV-2 mRNA vaccine in adult patients with systemic sclerosis
title_sort antibody response to bnt162b2 sars-cov-2 mrna vaccine in adult patients with systemic sclerosis
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9132599/
https://www.ncbi.nlm.nih.gov/pubmed/35614287
http://dx.doi.org/10.1007/s10067-022-06219-7
work_keys_str_mv AT pellicanochiara antibodyresponsetobnt162b2sarscov2mrnavaccineinadultpatientswithsystemicsclerosis
AT campagnaroberta antibodyresponsetobnt162b2sarscov2mrnavaccineinadultpatientswithsystemicsclerosis
AT olivaalessandra antibodyresponsetobnt162b2sarscov2mrnavaccineinadultpatientswithsystemicsclerosis
AT leodorigiorgia antibodyresponsetobnt162b2sarscov2mrnavaccineinadultpatientswithsystemicsclerosis
AT miglionicomarzia antibodyresponsetobnt162b2sarscov2mrnavaccineinadultpatientswithsystemicsclerosis
AT colalilloamalia antibodyresponsetobnt162b2sarscov2mrnavaccineinadultpatientswithsystemicsclerosis
AT mezzaromaivano antibodyresponsetobnt162b2sarscov2mrnavaccineinadultpatientswithsystemicsclerosis
AT mastroianniclaudiomaria antibodyresponsetobnt162b2sarscov2mrnavaccineinadultpatientswithsystemicsclerosis
AT turrizianiombretta antibodyresponsetobnt162b2sarscov2mrnavaccineinadultpatientswithsystemicsclerosis
AT rosatoedoardo antibodyresponsetobnt162b2sarscov2mrnavaccineinadultpatientswithsystemicsclerosis